Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.19.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2019
Jun. 30, 2018
Current assets:    
Cash $ 4,421 $ 15,934
Accounts receivable - trade 97 75
Prepaid expenses and other current assets 290 276
Total Current Assets 4,808 16,285
Fixed assets, net of accumulated depreciation 24,380 25,152
Intangible assets, net of accumulated amortization 1,374 1,620
Security deposit 24 26
Total Assets 30,586 43,083
Current liabilities:    
Accounts payable (related party of $65 and $189 as of June 30, 2019 and 2018, respectively) 1,001 790
Accrued expenses (related party of $699 and $789 as of June 30, 2019 and 2018, respectively) 965 1,048
Capital lease obligation - current portion 213 197
Contract liabilities 1,279 0
Total Current Liabilities 3,458 2,035
Capital lease obligation - net of current portion 24,671 24,884
Total Liabilities 28,129 26,919
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized; 20,152,458 and 16,040,126 shares issued and outstanding as of June 30, 2019 and 2018, respectively 20 16
Additional paid-in capital 108,295 104,408
Accumulated other comprehensive loss (31) (30)
Accumulated deficit (105,821) (88,228)
Total iBio, Inc. Stockholders' Equity 2,463 16,166
Noncontrolling interest (6) (2)
Total Equity 2,457 16,164
Total Liabilities and Equity 30,586 43,083
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0